ZHENG Yijing,ZHANG Xiaolei,LIN Yan, et al. Experimental study on the development and targeting effect of nanoparticles of double-antibody complex and adriamycin loaded[J]. JOURNAL OF WEZHOU MEDICAL UNIVERSITY, 2015, 45(8): 547-.
Abstract：Objective: To synthesize double antibody complex-glycol chitosan doxorubicin nanoparticles (Abc-GC-Dox) and study its targeting effect of osteosarcoma in mice. Methods: Abc-GC-Dox and GC-Dox were prepared by emulsion polymerization method, in vitro immunofluorescence was used to study the intake test of HER2+carried MG-63 cells in Abc-GC-Dox and GC-Dox. Fourteen mice with osteosarcoma were randomly divided into 2 groups. After corresponding treatment, different drugs (Abc-GC-Dox and GC-Dox) were given via tailvein, and the targeting effect was observed. Results: Stable Abc-GC-Dox and the quantity of drug • loading and entrapment were gotten. Compare to GC-Dox, there was a better drug concentration in osteosarcoma in mice, which showed a well targeting effect in vivo. Conclusion: Abc-GC-Dox is successfully developed and the nanoparticles demonstrated targeting aggregating distribution. In future, Abc-GC-Dox can be a potential drug for the clinical treatment of tumors.
[1] Farokhzad OC, Cheng J, Teply BA, et al. Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo [J]. Proc Natl Acad Sci USA, 2006, 103(16): 6315-6320.
[2] Zhang Y, Kohler N, Zhang M. Surface modification of superparamagnetic magnetite nanoparticles and their intracellular uptake[J]. Biomaterials, 2002, 23(7): 1553-1561.
[3] Ambruosi A, Yamamoto H, Kreuter J. Body distribution of polysorbate-80 and doxorubicin-loaded [14C] poly (butyl cyanoacrylate) nanoparticles after i.v. administration in rats [J]. Drug Target, 2005, 13(10): 535-542.
[4] Box VG. The intercalation of DNA double helices with doxorubicin and nogalamycin[J]. Mol Graph Model, 2007,26(1): 14-19.
[5] 韩涛. 李富荣. 周汉新. 阿霉素纳米粒靶向药物制剂的研究进展[J]. 中国药物与临床, 2004, 4(10): 737-740.
[6] Wang ZH, Wang ZY, Sun CS, et al. Trimethylated chitosan-conjugated PLGA nanoparticles for the delivery of drugs to the brain[J]. Biomaterials, 2010, 31(5): 908-915.
[7] Strand SP, Lelu S, Reitan NK, et al. Varum KM. Molecular design of chitosan gene delivery systems with an optimized balance between polyplex stability and polyplex unpacking [J]. Biomaterials, 2010, 31(5): 975-987.
[8] Lee JH, Jung SW, Kim IS. Polymeric nanoparticle composed of fatty acids and poly (ethylene glycol) as a drug carrier[J]. Int J Pharm, 2003, 251(1-2): 23-32.
[9] Moghimi SM, Hunter AC, Murray JC. Long-circulating and target-specific nanoparticles:theory to Particle[J]. Pharmacol Rev, 2001, 53(2): 283-318.
[10] Thrall JH. Nanotechnology and medicine[J]. Radiology, 2004, 230(2): 315-318.
[11] Slamon DJ, Godolphin W, Jones LA, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer[J]. Science, 1989, 244(4905): 707-712.
[12] Moasser MM. The oncogene HER2: its signaling and trans-forming functions and its role in human cancer pathogenesis [J]. Oncogene, 2007, 26(45): 6469-6487.
[13] Verri E, Guglielmini P, Puntoni M, et al. HER2/neu oncoprotein overexpression in epithelial ovarian cancer: evaluation of its prevalence and prognostic significance. Clinical study [J]. Oncology, 2005, 68(2-3): 154-161.
[14] Tsiambas E, Karameris A, Dervenis C, et al. HER2/neu expression and gene alterations in pancreatic ductal adenocarcinoma: a comparative immunohistochemistry and chromogenic in situ hybridization study based on tissue microarrays and computerized image analysis[J]. JOP, 2006, 7(3): 283-294.
[15] Ahmed N, Salsman VS, Yvon E, et al. Immunotherapy for osteosarcoma: genetic modification of T cells overcomes low levels of tumor antigen expression[J]. Mol Ther, 2009, 17 (10): 1779-1787.
